Phase 2: Clinical Trials

3 not yet recruiting, 2 recruiting. 5 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	5	Not yet recruiting 3, Recruiting 2

Follow Phase 2: new trials by email Literature Review of Phase 2 trials Research Report on Phase 2

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	40	2027-02-12	2026-09-23
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	200	2026-11-05	2026-05-28
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum Sacituzumab Tirumotecan - Phase 2, Sacituzumab Tirumotecan	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	20	2026-09-25	2026-10-02
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma Zanzalintinib, Pembrolizumab - Phase 2, Zanzalintinib	Phase 2	Recruiting	M.D. Anderson Cancer Center	20	2026-04-14	2026-08-20
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" Elranatamab - Phase 2, Radiotherapy-Induced Immune Priming	Phase 2	Recruiting	M.D. Anderson Cancer Center	34	2026-03-31	2026-09-18

Narrower conditions

Neoplasm Metastasis (2)  ·  Lymphoma, Follicular (1)  ·  Multiple Myeloma (1)  ·  Sarcoma (1)  ·  Triple Negative Breast Neoplasms (1)

Broader conditions

Neoplasms (5)  ·  Neoplasms by Histologic Type (3)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplastic Processes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Blood Protein Disorders (1)  ·  Breast Diseases (1)  ·  Breast Neoplasms (1)  ·  Cardiovascular Diseases (1)  ·  Hematologic Diseases (1)  ·  Hemorrhagic Disorders (1)

Interventions

pembrolizumab (2)  ·  CP protocol (1)  ·  Observation (1)

Sponsors

M.D. Anderson Cancer Center (5)

Countries

United States (5)

Top investigators

Christine Ye, MD (1)  ·  Clinton Yam, MD (1)  ·  Dai Chihara, MD (1)  ·  Michael S Nakazawa, MD (1)  ·  Van Morris, MD (1)